Clinical trials: Major Depressive Disorder, completed
Major Depression
Antidepressant Prophylaxis for Interferon-Induced Depression: Efficacy of Paroxetine
Objectives: 1. To determine whether paroxetine can prevent major depression in patients with hepatitis C (HCV) who are receiving pegylated-interferon (Peg-IFN). 2.
- Trial name
- NCT00357045
- Testing
- Paroxetine
- Sponsor
- Portland VA Medical Center
Major Depression, Chronic Primary Headache
An Open Trial of Duloxetine on Comorbid Major Depression and Chronic Headache
Background: Although major depression and chronic headache are strongly associated, there is insufficient evidence on the use of antidepressants for this specific comorbidity.
- Trial name
- NCT00531895
- Testing
- duloxetine
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- Kraepelin Psiquiatria Clinica
Major Depressive Disorder
Empower: tDCS for Major Depressive Disorder at Home
A two-center trial to investigate whether or not active stimulation with the Flow FL-100 tDCS device is superior to sham stimulation for the treatment of major depressive disorder when used at home.
- Trial name
- NCT05202119
- Testing
- Transcranial direct current stimulation
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 174 people
- Sponsor
- Flow Neuroscience AB
Major Depressive Disorder
Frequency and E-field Enhancement of ITBS for Depression (FREED)
The investigators propose a randomized 3-arm double-blinded parallel experimental trial (20 sessions over 4 weeks) in 75 patients with TRD.
- Trial name
- FREED (NCT06003309)
- Testing
- Transcranial Magnetic Stimulation (TMS) - Fully Individualized iTBS, Transcranial Magnetic Stimulation (TMS) - targeted-iTBS, Transcranial Magnetic Stimulation (TMS) - Standard-iTBS
- Where
- 2 sites in United States, Australia
- Volunteers
- 75 people
- Sponsor
- University of California, San Diego
Depressive Disorder, Major
Effects of Escitalopram on the Sleep EEG Power in Patients With Major Depressive Disorder
The main objective was to compare the differences of PSG parameters and plasma melatonin levels before and after treatment with escitalopram for 8 weeks.
- Trial name
- NCT04013464
- Testing
- Escitalopram
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Peking University Sixth Hospital
Schizophrenia, Bipolar Disorder
Dental Status of Patients With Severe Mental Illness
The investigators aim to assess the dental status of psychiatric patients suffering from severe mental illness (schizophrenia, bipolar disorder, ptsd, resistant depression).
- Conditions
- Schizophrenia, Bipolar Disorder, PTSD, Depression
- Trial name
- SMI-DENTAL (NCT01315509)
- Where
- Israel
- Volunteers
- 80 people
- Sponsor
- Hadassah Medical Organization
Major Depressive Disorder
A Study Comparing Duloxetine and Placebo in Assessing Energy and Vitality in Major Depressive Disorder (MDD) Patients
Study F1J-US-HMFS comprises two identical multicenter, 9-month, randomized, placebo-controlled, double-blind, trials (HMFSa and HMFSb).
- Trial name
- NCT00536471
- Testing
- Duloxetine hydrochloride
- Where
- 47 sites in United States, Puerto Rico
- Volunteers
- 776 people
- Sponsor
- Eli Lilly and Company
Unipolar Major Depressive Episode
Strategic Use of New Generation Antidepressants for Depression
The purpose of the study is to establish the optimum treatment strategy for first-line and second-line antidepressants in the acute phase treatment of major depression.
- Trial name
- SUN(^_^)D (NCT01109693)
- Testing
- Sertraline, Mirtazapine
- Where
- 2 sites in Japan
- Volunteers
- 2,011 people
- Sponsor
- Kyoto University
Mood Disorders, Major Depressive Disorder
Unobtrusive Monitoring of Affective Symptoms and Cognition Using Keyboard Dynamics (UnMASCK)
Mood disorders are associated with significant financial and health costs for the United States, partially due to cognitive problems in these patients that can worsen disease course and impair treatment response.
- Conditions
- Mood Disorders, Major Depressive Disorder, Bipolar Disorder I, Bipolar Disorder II
- Trial name
- UnMASCK (NCT04358900)
- Where
- United States
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- University of Illinois Chicago
COVID - 19, Depression - Major Depressive Disorder
The Efficacy of Long-Chain Fatty Acids, Eicosapentaenoic Acid (EPA) and Specialized Pro-Resolving Mediators (SPMs), in Treating Long COVID Neuropsychiatric Symptoms
Researchers conducted a 12-week, double-blind, randomized, placebo-controlled trial to assess the effectiveness of EPA or SPM treatments versus a placebo in managing Long COVID symptoms in adult patients.
- Trial name
- NCT07711444
- Testing
- Eicosapentaenoic acid (omega-3 fatty acid), Specialized Pro-Resolving Lipid Mediator
- Where
- Taiwan
- Volunteers
- 54 people
- Sponsor
- National Science and Technology Council, Taiwan
Depression, Depressive Disorder
Study Evaluating DVS-233 SR in Adult Outpatients With Major Depressive Disorder
The main objective of this study is to compare the antidepressant efficacy and safety of DVS-233 SR versus placebo in adult outpatients with Major Depressive Disorder.
- Conditions
- Depression, Depressive Disorder, Major Depressive Disorder
- Trial name
- NCT00092911
- Testing
- DVS-233 SR
- Volunteers
- 244 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Middle-aged Adults, Major Depressive Disorder
Daily Stress and Vascular Function in Midlife as a Risk Factor for Cognitive Decline
The goal of this pilot clinical trial is to begin to understand how day-to-day stress affects cardiovascular health and brain function in middle-aged adults.
- Trial name
- NCT06466655
- Testing
- MitoTempol, Lactated Ringer's (control)
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University of Delaware
Major Depressive Disorder
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study
This study will evaluate the efficacy and safety of ALKS 5461.
- Trial name
- NCT02218008
- Testing
- ALKS 5461
- Where
- 44 sites in United States, Canada and 2 more
- Volunteers
- 407 people
- Sponsor
- Alkermes, Inc.
Major Depressive Disorder
A Study of the Effect of LY2216684 on Lorazepam
The purpose of this study is to determine how much lorazepam gets into the blood and how long it takes the body to get rid of it when given together with LY2216684.
- Trial name
- NCT01275144
- Testing
- LY2216684, Lorazepam
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in the Treatment of Major Depressive Disorders
The purpose of this study is to demonstrate superior efficacy of Quetiapine fumarate sustained release (SEROQUEL) compared with placebo when used as a mono-therapy in the treatment of Major Depressive Disorders PLEASE NOTE…
- Trial name
- OPAL (NCT00326144)
- Testing
- Quetiapine fumarate
- Where
- 34 sites in United States
- Volunteers
- 310 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
Badalona Major Depressive Disorder Database Study
A retrospective study using a data base of anonymized medical records. The purpose of the study is to examine the different therapeutic strategies for the management of patients with major depressive disorder (MDD) and suboptimal…
- Trial name
- NCT01446692
- Where
- Spain
- Volunteers
- 2,260 people
- Sponsor
- AstraZeneca
Depressive Disorder, Major
Brain Network Dynamics of Depression During Esketamine Treatment
This is a monocentric, observational clinical trial investigating the effect of Esketamine on brain network activity and a belief updating task in people with depression.
- Trial name
- K-BRAINED (NCT06012916)
- Testing
- Esketamine nasal spray
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of North Carolina, Chapel Hill
Major Depression
Psychotherapy Plus: Combining Cognitive Behavioral Therapy With tDCS
The study will investigate whether cognitive behavioral psychotherapy (CBT) combined with prefrontal transcranial direct current stimulation (tDCS) is more efficacious with regard to symptom reduction in depressed patients than…
- Trial name
- NCT02633449
- Testing
- cognitive behavioral therapy, tDCS
- Where
- Germany
- Volunteers
- 209 people
- Sponsor
- Charite University, Berlin, Germany
Major Depressive Disorder
A Long-Term Safety Study of ALKS 5461
This is a 52-week open-label study to evaluate the safety and tolerability of ALKS 5461.
- Trial name
- NCT02141399
- Testing
- ALKS 5461
- Where
- 158 sites in United States, Australia and 6 more
- Volunteers
- 1,485 people
- Sponsor
- Alkermes, Inc.
Major Depressive Disorder
A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD)
This open label 52-week clinical trial is designed to assess the safety and tolerability of vilazodone and to analyze genetic markers of response to vilazodone in adult patients diagnosed with MDD.
- Trial name
- NCT00644358
- Testing
- vilazodone
- Where
- 38 sites in United States
- Volunteers
- 616 people
- Sponsor
- Forest Laboratories
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.